These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26149041)

  • 1. Antiplatelet drugs: which targets for which treatments?
    Gachet C
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S313-22. PubMed ID: 26149041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolution of antiplatelet therapy in cardiovascular disease.
    Yousuf O; Bhatt DL
    Nat Rev Cardiol; 2011 Jul; 8(10):547-59. PubMed ID: 21750497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
    McFadyen JD; Schaff M; Peter K
    Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Clopidogrel in 2020: A Reappraisal.
    Patti G; Micieli G; Cimminiello C; Bolognese L
    Cardiovasc Ther; 2020; 2020():8703627. PubMed ID: 32284734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
    Lettino M; Leonardi S; De Maria E; Halvorsen S
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):61-70. PubMed ID: 28618904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Prog Cardiovasc Dis; 2015; 58(3):267-77. PubMed ID: 26277706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.
    Dash D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet function testing and tailored antiplatelet therapy.
    Janssen PW; ten Berg JM
    J Cardiovasc Transl Res; 2013 Jun; 6(3):316-28. PubMed ID: 23543615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.